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Abstract 
Background: Osteosarcoma is the most common bone malignancy in children and adolescents, and 20%–30% of 
the patients suffer from poor prognosis because of individual chemoresistance. The Hippo/yes‑associated protein 
(YAP) signaling pathway has been shown to play a role in tumor chemoresistance, but no previous report has focused 
on its involvement in osteosarcoma chemoresistance. This study aimed to investigate the role of the Hippo/YAP sign‑
aling pathway in osteosarcoma chemoresistance and to determine potential treatment targets.
Methods: Using the Cell Titer‑Glo Luminescent cell viability assay and flow cytometry analysis, we determined the 
proliferation and chemosensitivity of YAP‑overexpressing and YAP‑knockdown osteosarcoma cells. In addition, using 
western blotting and the real‑time polymerase chain reaction technique, we investigated the alteration of the Hippo/
YAP signaling pathway in osteosarcoma cells treated with chemotherapeutic agents.
Results: Mammalian sterile 20‑like kinase 1 (MST1) degradation was increased, and large tumor suppressor kinase 
1/2 (LATS1/2) total protein levels were decreased by methotrexate and doxorubicin, which increased activation and 
nuclear translocation of YAP. Moreover, YAP increased the proliferation and chemoresistance of MG63 cells.
Conclusions: The Hippo/YAP signaling pathway plays a role in osteosarcoma chemoresistance, and YAP is a potential 
target for reducing chemoresistance.
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Background
Osteosarcoma is the most common bone malignancy in 
children and adolescents. Since the introduction of neo-
adjuvant chemotherapy (chemotherapy before treatment) 
in the 1980s, the prognosis of osteosarcoma patients has 
improved markedly [1]. However, in the past 10  years, 
the survival rate has risen only slightly. Currently, the 
consensus is that poor chemotherapeutic effect on 
some patients is the primary obstacle to a higher sur-
vival rate of osteosarcoma patients [2]. Methotrexate and 
doxorubicin are the most commonly used drugs for the 
treatment of osteosarcoma, and resistance to them sub-
stantially decreases patients’ survival rates. Thus, many 
studies have investigated the mechanism of chemore-
sistance to methotrexate and doxorubicin, including 
impaired intracellular transportation components [3], 
inactivation of chemotherapeutic drugs [4], DNA self-
repair enhancements [5], cell signaling transduction tur-
bulence [6], microRNA dysregulation [7], and autophagy 
overreaction [8]. Nevertheless, for patients with osteo-
sarcoma, the key mechanism of chemoresistance is still 
inconclusive. This motivated us to investigate alternative 
mechanisms for osteosarcoma chemoresistance.
The Hippo/yes-associated protein (YAP) signaling 
pathway was originally found in the Drosophila and has 
been proven to modulate organ size [9]. Its key com-
ponents include mammalian sterile 20-like kinases 1/2 
(MST1/2), salvador family WW domain-containing 
protein 1 (SAV1), large tumor suppressor kinases 1/2 
(LATS1/2), YAP, transcriptional co-activator with PDZ-
binding motif (TAZ), and transcriptional enhancer 
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factor domain family members 1–4 (TEAD1–4) [10]. In 
humans, MST1/2 combines with SAV1 to form an acti-
vated complex that initiates LATS1/2 phosphorylation 
[11–13]. Once activated, LATS1/2 further promotes the 
signaling cascade by phosphorylating YAP at Ser127 or 
TAZ at Ser89. Phosphorylated YAP then binds to 14-3-3 
protein and remains in the cytoplasm for degradation 
[14–16]. Dephosphorylated YAP translocates into the 
nucleus and binds to TEAD1–4, which activates down-
stream genes to support proliferation and inhibit apopto-
sis [17, 18]. The Hippo/YAP signaling pathway is involved 
in tumor chemoresistance. Mao et al. [19] reported that 
resistance to cisplatin is increased by YAP2 and silent 
mating type information regulation 2 homolog 1 (SIRT1) 
in hepatocellular carcinoma (HCC) cells, indicating that 
both YAP2 and SIRT1 protect HCC cells from the chem-
otherapeutic drug cisplatin. Similarly, ovarian cancer 
cells with knockdown of YAP/TEAD showed increased 
sensitivity to cisplatin, paclitaxel, and bleomycin [20]. 
Moreover, verteporfin, a YAP1 inhibitor, promotes sen-
sitivity to 5-fluorouracil and docetaxel by directly inhib-
iting YAP1 and endothelial growth factor receptor in 
esophageal cancer cells [21]. Although many studies have 
investigated the role of the Hippo/YAP signaling pathway 
in chemoresistance, little is known about its function in 
osteosarcoma chemoresistance.
In this study, we try to find the role of Hippo/YAP sign-
aling pathway in methotrexate- or doxorubicin-treated 
MG63 and U2OS osteosarcoma cells. We hope our 




Human osteosarcoma cell lines MG63 and U2OS were 
purchased from Cell Resource Center of Shanghai Insti-
tutes for Biological Sciences (Shanghai, China) and cul-
tured in Minimal Essential Medium (Gibco, Waltham, 
Massachusetts, USA) with 10% fetal bovine serum (Bio-
logical Industries, Kibbutz Beit Haemek, Israel), 1% 
non-essential amino acid (Gibco), and penicillin/strepto-
mycin (Gibco) in a humidified incubator under 95% air 
and 5% CO2 at 37 °C. All other cell culture materials were 
obtained from Gibco; all chemicals were obtained from 
Sigma-Aldrich (St. Louis, Missouri, USA).
Virus packaging and infection
pQCXIH empty vector and pQCXIH-YAP constructs 
were gifts from Bin Zhao (Zhejiang University, China) 
[18]. pLKO empty vector and pLKO-YAP-knockdown 
expressing lentivirus were also constructed to obtain YAP 
knockdown cell lines. MG63 cells were infected with ret-
rovirus that expresses empty vector and wild-type (WT) 
YAP separately to generate control and YAP-overex-
pressing stable cell lines. pLKO empty vector and pLKO-
YAP-knockdown expressing lentivirus were used to treat 
MG63 cells to generate control and YAP-knockdown sta-
ble cell lines. Hygromycin and blasticidin screening was 
performed 48 h after infection.
RNA extraction and quantitative real‑time polymerase 
chain reaction (RT‑PCR) analysis
Total RNA was isolated from cells using TRIzol reagent 
(Invitrogen-Life Technologies, Waltham, Massachu-
setts, USA). The reverse transcription products were 






MG63 and U2OS cells were fixed using 4% paraformalde-
hyde in phosphate buffered saline (PBS) for 15 min. After 
permeabilization, using 0.1% Triton X-100 in PBS and 
blocking in 3% bovine serum albumin in PBS, the cells 
were incubated in primary antibodies overnight at 4  °C. 
Alexa Fluor 546-conjugated secondary antibodies (Inv-
itrogen-Life Technologies; 1:1000 dilution) were used. 
The samples were mounted using ProLong Gold Antifade 
Reagent with DAPI (Invitrogen-Life Technologies), and 
immunofluorescence was detected using an Olympus 
confocal microscope.
Co‑immunoprecipitation
Cells were collected, and proteins were solubilized 
in immunoprecipitation buffer (50  mM Tris pH 8.0, 
150 mM NaCl, 1% NP40, 1% protease inhibitor cocktail) 
at 4  °C. Then, 1 mg of lysed protein was incubated with 
YAP antibody (ABclonal Biotech, A1002, College Park, 
Maryland, USA) and precipitated with protein A or G 
agarose (Upstate Biotechnology, Lake Placid, New York, 
USA) at 4  °C overnight. The immune complex was col-
lected, washed three to five times, and probed with 14-3-
3β antibody (Cell Signaling Technology, #9636, Danvers, 
Massachusetts, USA) and YAP antibody (ABclonal 
Biotech).
Cell counting
MG63 cells were cultured in 96-well flat plates for 6 days. 
Before seeding, cell numbers were calculated using a 
countess automated cell counter (Invitrogen-Life Tech-
nologies) to keep the initial cell numbers equal. Culture 
media were rejuvenated every 48  h, and total cell num-
bers of cells were counted every 24 h. In this study, three 
independent experiments were performed.
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Cell viability assay
Cell Titer-Glo Luminescent Cell Viability Assay (Pro-
mega, Madison, Wisconsin, USA) was used to moni-
tor cell total adenosine triphosphate (ATP). MG63 cells 
were seeded in a 96-well flat plate for 24 h and exposed 
to methotrexate (20  mM) or doxorubicin (10  μM) for 
another 24  h. Then, the Cell Titer-Glo reagent was 
added to the cells for 10 min. ATP was measured using 
a reporter luminometer. Relative cell viability was calcu-
lated according to the manufacturer’s instructions. This 
experiment was repeated three times.
Cell apoptosis assay
Cell apoptosis was examined by flow cytometry analysis 
using the Annexin V-FITC and propidium iodide (PI) 
double-staining technique. MG63 cells were seeded in 
a 24-well culture plate at greater than 80% confluence 
and subjected to methotrexate (20  mM) or doxorubicin 
(10  μM) treatments for 24  h. Cells were stained follow-
ing the Annexin V-fluorescein isothiocyanate (FITC) cell 
apoptosis detection kit’s instructions (Beyotime Biotech-
nology, C1062, Shanghai, China). To confirm our results, 
three independent experiments were conducted.
Western blotting
Cells were lysed in a RIPA buffer (Beyotime Biotechnol-
ogy), and total protein concentration was measured using 
a BIO-RAD Quick Start Bradford Dye Reagent (#500-
0205; Bio-Rad Laboratories, Hercules, California, USA) 
according to the manufacturer’s instructions. Western 
blotting procedures were performed as reported pre-
viously [22]. Grayscale analysis was conducted using 
Image J software (National Institute of Health, Bethesda, 
Maryland, USA), and results were calculated from three 
independent experiments. The primary antibodies used 
in our experiments were as follows: YAP (ABclonal Bio-
tech, A1002), Phospho-YAP (Cell Signaling Technol-
ogy, #13008), LATS2 (Sigma-Aldrich, WH0007004M1), 
LATS1 (Bethyl laboratory, A300-477A; Montgomery, 
Texas, USA), MST1 (Cell Signaling Technology, #3682), 
14-3-3β (Cell Signaling Technology, #9636), and GAPDH 
(Cell Signaling Technology, #5174).
Statistical analysis
Results are presented as mean  ±  standard deviation. 
Comparisons between two groups were assessed using 
the unpaired Student’s t test. Cyclohexamide grayscale 
comparison was made using the paired t test. P values 
less than 0.05 were considered statistically significant. 
All statistical analyses were conducted using GraphPad 
Prism software (GraphPad Software, San Diego, Califor-
nia, USA).
Results
YAP regulated the proliferation and chemoresistance 
of osteosarcoma cells
To investigate the function of the Hippo/YAP pathway in 
osteosarcoma chemoresistance, we successfully established 
stable YAP-overexpressing and YAP-knockdown MG63 
cell lines by retrovirus and lentiviral infection. As shown 
in Fig. 1a, overexpressing and knockdown of YAP resulted 
in accelerated and slowed cell proliferation, as detected 
by cell number counting. Moreover, cell viability assay 
showed that overexpression of YAP increased the viability 
of MG63 cells treated with high-concentration methotrex-
ate (20  mM) or doxorubicin (10  μM) (Fig.  1b). Annexin 
V-FITC/PI staining and flow cytometry analysis confirmed 
the protective function of YAP in response to methotrexate 
(20 mM) or doxorubicin (10 μM), as the apoptosis of YAP-
overexpressing cells was significantly lower than that of the 
control (P = 0.001 and P = 0.043, respectively). Addition-
ally, YAP-knockdown cells demonstrated increased sensi-
tivity to methotrexate and doxorubicin (Fig. 1c). Together, 
these data showed that YAP increased cell growth and the 
chemoresistance of osteosarcoma cells.
Methotrexate and doxorubicin induced YAP activation 
in MG63 and U2OS osteosarcoma cells
To further investigate the role of the Hippo/YAP pathway 
in osteosarcoma chemoresistance, we evaluated LATS1/2 
total protein level and Ser127 phosphorylation of YAP 
in osteosarcoma cells. Before Western blotting analy-
sis, MG63 and U2OS were treated with methotrexate 
or doxorubicin at different concentrations for 24  h. We 
observed that LATS1/2 total protein decreased in osteo-
sarcoma cells treated with methotrexate or doxorubicin 
(Figs. 2, 3). As shown in Fig. 2a and c, phosphorylation of 
YAP decreased significantly in a concentration-depend-
ent manner after doxorubicin treatment. Similar results 
were found after treatment of methotrexate (Fig. 2b, d). 
Grayscale comparison of western blotting results showed 
that both methotrexate and doxorubicin could induce 
YAP activation, suggesting that YAP plays a role in osteo-
sarcoma chemoresistance.
Methotrexate and doxorubicin induced YAP nuclear 
translocation
Since YAP phosphorylation at Ser127 determines its 
location in either the cytoplasm or the nucleus [23], 
using immunofluorescence staining we examined the 
intracellular location of YAP in methotrexate- or doxo-
rubicin-treated MG63 and U2OS cells. We found that 
YAP translocated to the nucleus in both MG63 and 
U2OS cells after methotrexate or doxorubicin treatment 
(Fig.  4a, b). 14-3-3 protein is well known for its critical 
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role in inhibiting the nuclear translocation of YAP. To 
further validate the effect of methotrexate and doxo-
rubicin on YAP activity, we determined the interaction 
between YAP and 14-3-3. Cells exposed to methotrex-
ate or doxorubicin were harvested for co-immunopre-
cipitation studies. Consistent with the results from the 
immunofluorescence staining assays, methotrexate 
and doxorubicin dramatically reduced the interaction 
between YAP and 14-3-3 (Fig.  4c, d). Methotrexate and 
doxorubicin decreased the interaction between YAP and 
14-3-3β and induced YAP nuclear translocation, indicat-
ing that both are capable of activating YAP.
Fig. 1 Yes‑associated protein (YAP) increases the proliferation and chemoresistance of MG63 osteosarcoma cells. a Control and YAP‑overexpress‑
ing/knockdown MG63 cells were seeded at the same concentration, and cell numbers were counted every 24 h. Data are shown as mean ± stand‑
ard deviation (SD). Compared with control (t test, n = 3), **P < 0.01, and *P < 0.05. Results show that overexpression of YAP accelerated MG63 cell 
proliferation and knockdown of YAP decreased cell proliferation. b Cell viability was analyzed by detecting total cellular adenosine triphosphate in 
methotrexate (MTX) (20 mM)‑ or doxorubicin (DOX) (10 μM)‑treated control and YAP‑overexpressing MG63 cells. Data are shown as mean ± SD. 
Compared with control (t test, n = 3), **P < 0.01, and ##P < 0.01. Overexpression of YAP increased the viability of MG63 cells treated with MTX 
(20 mM) or DOX (10 μM). c Left panel representative images of flow cytometry analysis of YAP‑overexpressing and YAP‑knockdown MG63 cells 
treated with MTX (20 mM) or DOX (10 μM) and stained by Annexin V‑fluorescein isothiocyanate (FITC) and propidium iodide. Due to the natural 
fluorescence of DOX, we calculated only Annexin V‑FITC‑positive cells in DOX‑treated cells. Right panel Quantitative analysis of apoptosis percent‑
ages according to the results of left panel. Data are shown as mean ± SD. Compared with control (t test, n = 3), *P < 0.05, **P < 0.01, #P < 0.05, and 
##P < 0.01. The flow cytometry results showed that YAP increased the chemoresistance of osteosarcoma cells and knockdown of YAP increased the 
chemosensitivity of osteosarcoma cells. YAP‑KD, knockdown of YAP
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Methotrexate and doxorubicin decreased MST1 expression 
by altering its protein stability
MST1 is a key component of the Hippo signaling path-
way. To better understand MST1’s role in osteosarcoma 
chemoresistance, we examined its protein level. As shown 
in Fig. 5a, total protein of MST1 remarkably declined in 
methotrexate- or doxorubicin-treated osteosarcoma cells. 
However, after methotrexate and doxorubicin treatment, 
we did not observe the down-regulation of MST1 mRNA 
level (Fig.  5b), suggesting that doxorubicin and metho-
trexate reduce MST1 expression at the protein level. Then, 
U2OS cells were treated with cycloheximide (a common 
inhibitor of protein biosynthesis in eukaryotic organisms) 
for the times indicated and harvested for analysis of the 
MST1 protein level. As shown in Fig.  5c, methotrexate 
and doxorubicin accelerated degradation of MST1, sug-
gesting that MST1 is destabilized by methotrexate and 
doxorubicin, which is responsible for the activation of 
YAP induced by methotrexate and doxorubicin.
Discussion
Although many reports have shown that the Hippo/YAP 
signaling pathway is involved in tumorigenesis, little is 
known about its role in osteosarcoma chemoresistance. 
In the present study, we showed that, in osteosarcoma 
cells, methotrexate and doxorubicin activated YAP, pro-
moting its nuclear translocation by accelerating MST1 
protein degradation and decreasing LATS1/2 protein 
level. Furthermore, YAP regulated the proliferation and 
chemoresistance in MG63 osteosarcoma cells, indicating 
that the Hippo/YAP pathway plays a role in osteosarcoma 
chemoresistance (Fig. 6).
Current management of osteosarcoma patients focuses 
on neoadjuvant chemotherapy plus surgery. However, 
Fig. 2 MTX and DOX induce YAP activation in MG63 and U2OS osteosarcoma cells. a, b Left panel Western blotting representative image of large 
tumor suppressor kinase 2 (LATS2), YAP, and YAP phosphorylation at Ser127 in MG63 cells with indicated concentrations of MTX or DOX treatments. 
Right panel Grayscale comparison of phosphorylated YAP to YAP total protein. Data are shown as mean ± SD. Compared with control (t test, n = 3), 
**P < 0.01. YAP phosphorylation level at Ser127 and LATS2 protein level in MG63 cells was decreased by MTX and DOX. c, d Left panel Western blot‑
ting representative image of LATS2, YAP, and YAP phosphorylation at Ser127 in U2OS cells with indicated concentrations of MTX or DOX treatments. 
Right panel Grayscale comparison of phosphorylated YAP to YAP total protein. Data are shown as mean ± SD. Compared with control (t test, n = 3), 
**P < 0.01. YAP phosphorylation level at Ser127 and LATS2 protein level in U2OS cells was decreased by MTX and DOX. P-YAP YAP phosphorylation
Fig. 3 LATS1/2 total protein decreases in response to MTX/DOX 
treatment in osteosarcoma cells. a Grayscale comparisons of LATS2 
total protein to that of GAPDH in U2OS cells, according to the west‑
ern blotting results in Fig. 2c, d. The error bars represent mean ± SD. 
Compared with control (t test, n = 3), *P < 0.05 and #P < 0.05. LATS2 
protein level was decreased by MTX and DOX in U2OS cells. b Rep‑
resentative image of LATS1 total protein in MG63 cells treated with 
indicated concentrations of MTX or DOX. LATS1 protein level was 
decreased by MTX and DOX in MG63 cells
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many patients die from tumor metastases because of 
poor response to chemotherapy. In the past 10 years, sev-
eral cell signaling pathways, including phosphoinositide 
3 kinase (PI3 K)/Akt, extracellular signal-regulated kinase 
(ERK)1/2, Notch, and Wnt-β-catenin, have been identi-
fied to be involved in osteosarcoma chemoresistance [24–
26]. Recently, the Hippo/YAP signaling pathway has been 
shown to modulate organ size [9, 27]. Moreover, other 
studies have shown that YAP promotes neoplastic cell pro-
liferation and accelerates oncogenic senescence [28, 29]. 
Mao et  al. [19] showed that SIRT1 increases the interac-
tion between YAP2 and TEAD4 and enhances resistance 
to the anti-cancer drug cisplatin by deacetylating YAP2 in 
HCC cells. Phosphorylation-defective YAP overexpression 
makes ovarian cancer cells much more resistant to cisplatin 
[30]. Nevertheless, the relationship between osteosarcoma 
chemoresistance and the Hippo/YAP signaling pathway 
is still unclear. To our knowledge, our study is the first to 
focus on the function of the Hippo/YAP signaling pathway 
in osteosarcoma chemoresistance. We found that, with 
methotrexate and doxorubicin treatment, YAP increases 
MG63 cell proliferation and cytotoxic survivability. 
Accordingly, methotrexate and doxorubicin inhibit the 
phosphorylation of YAP. Similar to doxorubicin, cisplatin 
also inhibits YAP phosphorylation at Ser 127 in HCC cells 
[19]. Activated YAP then translocates to the nucleus and 
enhances the chemoresistance of osteosarcoma cells.
We also determined that reduced MST1 and LATS1/2 
protein level in response to methotrexate and doxoru-
bicin may cause up-regulation of YAP activity. Previously, 
our colleagues [31] reported that c-Abl stabilizes MST1 
protein level and protects it from ubiquitination by phos-
phorylating MST1 at Y433 in HEK 293T and Neuro2A 
cells. In addition, Ren et al. [32] found that proteasome-
mediated down-regulation of MST1 by heat shock pro-
tein 70 enhances resistance to cisplatin in prostate cancer 
cells. Autophagy is another regulated pathway of cellular 
degradation. In various tumor cells, increased autophagy 
has shown protective effects against cytotoxic agents [33, 
34]. MST1/2 directly phosphorylates LC3 and enhances 
the cell autophagy process [35]. Therefore, decrease of 
MST1 could decreases cell autophagy and then improve 
osteosarcoma chemosensitivity. As there is no evidence 
for lysosome-mediated degradation of MST1, we could 
Fig. 4 MTX and DOX induce YAP nucleus translocation. a, b MG63 and U2OS cells cultured on coverslips were exposed to MTX (100 μM) or DOX 
(1.5 μM) for 24 h. Endogenous YAP was stained using an anti‑YAP antibody (red), and nuclei were stained with DAPI (blue). The subcellular localiza‑
tion of YAP was quantified (lower panels). The error bars represent mean ± SD. Compared with control (N nucleus; C cytoplasm. t test, n = 100), 
**P < 0.01, ##P < 0.01. Results show that MTX and DOX promoted YAP nuclear translocation. c, d Co‑immunoprecipitation was applied to investigate 
the interaction between YAP and 14‑3‑3β in MG63 and U2OS cells. Cells were exposed to indicate concentrations of MTX or DOX for 24 h before 
co‑immunoprecipitation. The results were determined by western blotting and the interaction between YAP and 14‑3‑3β was decreased by MTX 
and DOX
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not confirm whether proteasomal or lysosomal degrada-
tion is responsible for the decrease of MST1 protein level 
in osteosarcoma cells treated with chemotherapeutic 
drugs. Further experiments are needed to address this.
Conclusions
In conclusion, our results suggest that the Hippo/YAP 
signaling pathway induces osteosarcoma chemoresist-
ance. The reduction in the concentration of MST1 and 
LATS1/2 proteins by methotrexate and doxorubicin leads 
to YAP activation and nuclear translocation. Moreover, 
YAP increases the proliferation and methotrexate/doxo-
rubicin resistance in MG63 cells. Taken together, our 
findings suggest that the decrease of YAP may improve 
osteosarcoma chemosensitivity.
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